Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material.
Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992.
Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.
From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet
Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice.
Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.
Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.
Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.
Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material.
We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.
Find out about our current vacancies at Berlin-Chemie directly on our career portal.
Within the Menarini Group, Berlin-Chemie is the regional headquarters for the CEE and CIS region and is responsible for more than 30 countries and their local subsidiaries.
As a reliable partner in the healthcare sector, we want to use our products and expertise to help solve the complex challenges in the healthcare sector in these regions. To this end, Berlin-Chemie has established strong partnerships at all levels in many countries. We support doctors and patients with high-quality medical products and technologies to improve the quality of life.
BERLIN-CHEMIE AG
Glienicker Weg 125
12489 Berlin, Deutschland
E-mail: info@berlin-chemie.de
Phone: +49 (0)30 6707-0
Fax: +49 (0)30 6707-2120
2017 - 06 - 21
Pomezia, June 21, 2017- Menarini Ricerche and the UK company Oxford BioTherapeutics (OBT) will present the latest data about their novel antibody drug-conjugate (ADC) MEN1309/OBT076, in development for solid and haematological tumors, at the 29th Pezcoller Symposium which will take place on June 22,23 2017 in Trento, Italy.
Results of the preclinical studies of the novel ADC, as well as the characterization of its target antigen Ly75/CD205, will be summarized in a poster entitled: “MEN1309/OBT076: a novel Antibody-Drug Conjugate targeting the Ly75/CD205 antigen”.
The poster will focus on the antitumor activity of MEN1309/OBT076 in vitro and in vivo. Indeed, MEN1309/OBT076 showed impressive anti-tumoral activity against NHL and triple negative breast cancer cell lines, in the corresponding xenograft models and in Patient-Derived Xenograft (PDX) models.
About MEN1309/OBT076
MEN1309/OBT076 is a fully humanized IgG1 monoclonal antibody conjugated to a potent cytotoxic maytansinoid toxin via a cleavable linker. The ADC is directed against a type I transmembrane glycoprotein and a C-type lectin receptor Ly75/ CD205, that is over-expressed in several solid tumors and non-Hodgking lymphomas (NHL).